$OTLK News

Outlook Therapeutics Heads Into Another FDA PDUFA Decision For Lytenava

Outlook Therapeutics Eye Drug Review Returns To FDA For Fourth Time

Outlook Therapeutics Says FDA Accepts Resubmitted BLA For ONS-5010/LYTENAVA For Treatment Of Neovascular Age-Related Macular Degeneration; PDUFA Target Action Date July 29

Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10

Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity

Outlook Therapeutics Resubmits Biologics License Application To FDA For ONS-5010/LYTENAVA To Treat Neovascular Age-Related Macular Degeneration

Outlook Therapeutics Announces $5M Registered Direct Offering Of 8,539,709 Shares At $0.5855/Share To GMS Ventures For Working Capital And General Corporate Purposes

Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA

BTIG Downgrades Outlook Therapeutics to Neutral

Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates

Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Outlook Therapeutics Q2 Adj. EPS $(0.16) Misses $(0.12) Estimate, Sales $128.000K Miss $4.400M Estimate

Outlook Therapeutics Enters Sales Agreement With H.C. Wainwright To Offer And Sell Common Stock Up To $100M

Outlook Therapeutics Terminates Offering Agreement With BTIG Effective May 12

Outlook Therapeutics Enter $100M Offering Agreement With H.C. Wainwright

Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Outlook Therapeutics Announces $5M Registered Direct Offering For 16,129,033 Shares At $0.31/Share

Outlook Therapeutics Announces $5M Registered Direct Offering For 16,129,033 Shares At $0.31/Share

Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)